All‐cause mortality · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80 mmHg or greater
It is very uncertain whether evening changes all‐cause mortality compared with morning dosing regimen (very low certainty).
1 finding from 1 review
All‐cause mortality · patients with hypertension
CCBs showed no clear difference in all‐cause mortality compared with diuretic (moderate certainty).
1 finding from 1 review
All‐cause mortality · patients with hypertension
CCBs showed no clear difference in all‐cause mortality compared with ACE inhibitor (low certainty).
1 finding from 1 review
All‐cause mortality · patients with hypertension
CCBs showed no clear difference in all‐cause mortality compared with ARB (moderate certainty).
1 finding from 1 review
All‐cause mortality · patients with hypertension
CCBs showed no clear difference in all‐cause mortality compared with β‐blocker (moderate certainty).
1 finding from 1 review
All‐cause mortality · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy
It is very uncertain whether antihypertensive therapy changes all‐cause mortality compared with placebo or no treatment (very low certainty).
1 finding from 1 review
All‐cause mortality · people with primary hypertension
Renin inhibitors showed no clear difference in all‐cause mortality compared with ACE inhibitors (low certainty).
1 finding from 1 review
All‐cause mortality · Older adults, 50 years and older
Discontinuation by no treatment/placebo of antihypertensives showed no clear difference in all‐cause mortality compared with continuation (low certainty).
1 finding from 1 review
All‐cause mortality · adults aged 18‐59 years with primary hypertension (mild to moderate systolic or diastolic hypertension)
Antihypertensive drug therapy showed no clear difference in all‐cause mortality compared with control (low certainty).
1 finding from 1 review
All‐cause mortality · older adults with primary hypertension
Higher BP target (< 150‐160/95‐105 mmHg) showed no clear difference in all‐cause mortality compared with lower BP target (< 140/90 mmHg) (low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at 2 days ‐ immediate treatment · patients with acute myocardial infarction1
The intervention leads to lower all‐cause mortality at 2 days ‐ immediate treatment (high certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at 2 days ‐ immediate treatment · acute myocardial infarction1
The intervention showed no clear difference in all‐cause mortality at 2 days ‐ immediate treatment (high certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at 2 days ‐ immediate treatment · patients with acute myocardial infarction1
The intervention showed no clear difference in all‐cause mortality at 2 days ‐ immediate treatment (low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at 2 days ‐ immediate treatment · patients with acute myocardial infarction or stroke1
It is very uncertain whether the intervention changes all‐cause mortality at 2 days ‐ immediate treatment (very low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at 10 days‐ short‐term treatment · patients with acute myocardial infarction1
The intervention leads to lower all‐cause mortality at 10 days‐ short‐term treatment (high certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at 10 days ‐ short‐term treatment · acute myocardial infarction1
The intervention leads to lower all‐cause mortality at 10 days ‐ short‐term treatment (high certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at 10 days ‐ short‐term treatment · patients with acute myocardial infarction1
The intervention showed no clear difference in all‐cause mortality at 10 days ‐ short‐term treatment (high certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at 10 days ‐ short‐term treatment · patients with acute myocardial infarction or stroke1
It is very uncertain whether the intervention changes all‐cause mortality at 10 days ‐ short‐term treatment (very low certainty).
1 finding from 1 review